Exhibit 99.1
Delcath Systems Receives Permanent J-Code (J9248) for
HEPZATO (melphalan/Hepatic Delivery System) Effective April 1, 2024
NEWS PROVIDED BY
Delcath Systems, Inc. ☐
31 Jan, 2024,
08:00 ET
NEW YORK, Jan. 31, 2024 /PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on
the treatment of primary and metastatic cancers of the liver, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a permanent and product-specific
J-code (J9248) for HEPZATO. The J-code will become effective on April 1, 2024.
J-codes are a form of Healthcare Common Procedure Coding System Level II identifiers used by payors to streamline the
billing of Medicare Part B drugs. In its summary of Delcaths application for the J-code, CMS stated that [e]xistng melphalan hydrochloride is FDA approved at 0.25 mg/kg via intravenous infusion for
patients with multiple myeloma and is not substitutable for the melphalan hydrochloride in the HEPZATO KIT which is approved at 3.0 mg/kg via intraarterial delivery for patients with metastatic ocular melanoma.
The HEPZATO KIT is a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than
50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
We believe that the establishment of the permanent J-code for HEPZATO will facilitate patient access to this
important treatment, said Gerard Michel, Delcaths Chief Executive Officer. This is a significant step towards accurate and efficient reimbursement of the HEPZATO KIT, facilitating access for patients.
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The companys proprietary
products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to
administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
In the United
States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcaths proprietary Hepatic Delivery
System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which
can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma
(mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.
In Europe, the device-only configuration of the
HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at
major medical centers to treat a wide range of cancers of the liver.